GSK is to withdraw its multiple myeloma therapy Blenrep (belantamab mafodotin) from the US market following a US Food and Drug Administration request, as the drug has failed to show significant benefits for patients in a confirmatory study.
Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes
But A Comeback Remains Possible
Blenrep’s withdrawal will add to GSK’s blockbuster drought, and hopes of separate trial success for the BCMA-targeting drug in earlier stage myeloma may now be harder to achieve.
More from New Products
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
• By
Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.